Launch of Interferon-Free Regimens Will Fundamentally Change the HCV Treatment Algorithm in the US, Japan, and Many European Countries
Dallas, TX (PRWEB) September 28, 2014
The Hepatitis C Virus Market generated approximately $4.2 billion from global sales in 2012. Over the next 10 years, this market is expected to grow to reach $12.8 billion, with major growth occurring in the main Hepatitis C Virus Markets, such the US.
Some of the main drivers of market growth are expected to be:
- Introduction of interferon-free HCV regimens, which have an improved side effect profile compared with the first-generation direct-acting antiviral (DAA) and interferon-sparing HCV therapies
- The arrival of fixed-dose combination therapies, which are expected to help simplify treatment
- Increase in patient awareness of HCV through screening initiatives and public awareness campaigns
- A paradigm shift toward the preventative treatment of HCV in most countries
The barriers limiting the growth of the market include:
- Limited patient awareness regarding the threat of HCV
- Concerns over decreasing healthcare spending as part of government austerity measures
Complete Report Details Available @ http://www.marketoptimizer.org/pharmapoint-hepatitis-c-virus-global-drug-forecast-and-market-analysis-to-2022-event-driven-update.html .
Key Questions Answered
- How quickly, and to what extent, will interferon-sparing and all-oral regimens replace Incivek and Victrelis in the treatment algorithm?
- What role, if any, will interferon-based therapies have in the HCV treatment landscape over the next decade?
- Which novel HCV therapies will face adoption challenges in the market? What is the projected uptake of new drugs, such as Merck’s MK-5172/MK-8742, over the forecast period?
- Will the reduced pill burden and increased convenience of fixed-dose, all-oral combination therapies lead to their widespread uptake?
- How will pricing influence the use of next-generation DAAs?
- Which HCV regimen(s) in development are physicians most excited about?
- Patient awareness is anticipated to increase in response to government education and screening initiatives.
- Interferon use is predicted to drastically decrease over the next 10 years.
- The launch of next-generation, all-oral DAA regimens is expected to streamline the HCV treatment algorithm.
- The approval of more-tolerable HCV therapies is likely to result in patients deciding to undergo treatment.
- Fixed-dose combination therapies are expected to seize market share due to their reduced pill burden and convenience.
Order a Purchase Copy @ http://www.marketoptimizer.org/contacts/purchase?rname=10698 .
(This is a premium report priced at US$10995 for a single user License.)
Below Company Profiles include in Report:
- Bristol-Myers Squibb
- Boehringer Ingelheim
- Mitsubishi Tanabe Pharmaceutical Corporation
Pharma Giants Battle as New Entrants Leverage Interferon-Sparing and Interferon-Free HCV Regimens to Capture Market Share
Roche and Merck had been the HCV market leaders for the better part of two decades. The companies leveraged their interferon and ribavirin drugs to quickly capture market share. Roche’s and Merck’s commitment to innovation later resulted in the launch of peginterferon HCV therapies, which quickly overtook the market, but both companies fell behind in the race to develop the first DAA therapies for HCV. This enabled Vertex to establish itself as the leader in the US with the launch of Incivek (telaprevir) in 2011. Janssen was also able to capitalize on the demand for DAAs to become the front-runner in many European markets through the launch of Incivo (telaprevir). The arrival of interferon-sparing regimens, most notably Gilead’s Sovaldi (sofosbuvir) and Janssen’s Olysio (simeprevir), in late 2013 has resulted in the reduced uptake of the first-generation DAAs as patients wait for even better therapies on the horizon.
Companies Prioritize the Development of All-Oral HCV Regimens
The current HCV therapies have satisfactory efficacy, but they still require co-administration with peginterferon and ribavirin for the majority of patients. The shortcomings of the first-generation DAAs (Incivek and Victrelis [boceprevir]) and the first-to-market interferon-sparing (Sovaldi and Olysio) regimens have created an opportunity for the next-generation interferon-free therapies, especially in the US, Japan, and many European countries. GlobalData anticipates that more tolerable and convenient all-oral therapies will experience robust uptake in these markets.
AbbVie’s combination therapy (ABT-450/ombitasvir + dasabuvir) is expected to be among the first interferon-free HCV regimens to launch in several countries for GT1 patients. The regimen’s tolerability, efficacy in both treatment-naïve and treatment-experienced patients, and short duration of therapy are expected to result in it becoming a front-line therapy. GlobalData forecasts peak-year sales for the regimen of $2.2 billion in 2016. Other all-oral regimens, such as BMS’ daclatasvir/asunaprevir/BMS-791325 and Merck’s MK-5172/MK-8742, are also expected to seize market share from the interferon-sparing therapies, with peak-year sales of $1.0 billion in 2017 and $1.7 billion in 2019, respectively.
Explore more reports on Pharmaceuticals industry at http://www.marketoptimizer.org/category/life-sciences/pharmaceuticals .
MarketOptimizer.org is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.